Cardiome Pharma Corp. (CRME) EPS Estimated At $-0.20; Morgan Stanley Asia-pacific Fund (APF)’s Sentiment Is 0.32

April 23, 2018 - By Vivian Park

Analysts expect Cardiome Pharma Corp. (NASDAQ:CRME) to report $-0.20 EPS on May, 21.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.2 EPS. After having $-0.24 EPS previously, Cardiome Pharma Corp.’s analysts see -16.67% EPS growth. The stock decreased 0.87% or $0.02 during the last trading session, reaching $2.28. About 41,676 shares traded. Cardiome Pharma Corp. (NASDAQ:CRME) has declined 27.63% since April 23, 2017 and is downtrending. It has underperformed by 39.18% the S&P500.

Morgan Stanley Asia-pacific Fund Inc (APF) investors sentiment decreased to 0.32 in 2017 Q4. It’s down -0.61, from 0.93 in 2017Q3. The ratio has dropped, as 7 funds started new and increased stock positions, while 22 trimmed and sold stakes in Morgan Stanley Asia-pacific Fund Inc. The funds in our database now have: 8.39 million shares, down from 8.42 million shares in 2017Q3. Also, the number of funds holding Morgan Stanley Asia-pacific Fund Inc in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 7 Reduced: 15 Increased: 6 New Position: 1.

Investors sentiment decreased to 0.46 in 2017 Q4. Its down 0.63, from 1.09 in 2017Q3. It fall, as 6 investors sold Cardiome Pharma Corp. shares while 7 reduced holdings. 2 funds opened positions while 4 raised stakes. 12.53 million shares or 7.45% less from 13.54 million shares in 2017Q3 were reported. Morgan Stanley holds 0% or 13,590 shares in its portfolio. 486,613 are held by Renaissance Llc. Jpmorgan Chase & Com holds 0% or 161,450 shares in its portfolio. Scotia Capital owns 19,120 shares or 0% of their US portfolio. Virtu Fincl Limited Liability has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Deutsche Natl Bank Ag holds 29,300 shares or 0% of its portfolio. Valley Natl Advisers has 50 shares for 0% of their portfolio. Alphaone Serv Limited Com owns 10,625 shares or 0% of their US portfolio. Art Advsrs Ltd Limited Liability Company stated it has 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME). Rock Springs Limited Partnership holds 1.20M shares or 0.08% of its portfolio. California-based Wells Fargo Mn has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Pnc Financial Svcs Group stated it has 51,400 shares. Knott David M accumulated 67,978 shares. The Massachusetts-based Clough Cap Prns L P has invested 0.34% in Cardiome Pharma Corp. (NASDAQ:CRME). The Illinois-based Grp One Trading Lp has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME).

Among 6 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cardiome Pharma Corp had 17 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating by Zacks given on Tuesday, August 11. The firm has “Buy” rating given on Wednesday, April 4 by H.C. Wainwright. H.C. Wainwright initiated the stock with “Buy” rating in Wednesday, June 1 report. The firm has “Buy” rating by LB Securities given on Friday, August 14. The firm earned “Buy” rating on Wednesday, November 22 by H.C. Wainwright. Zacks downgraded the shares of CRME in report on Wednesday, August 26 to “Hold” rating. H.C. Wainwright maintained Cardiome Pharma Corp. (NASDAQ:CRME) on Tuesday, August 22 with “Buy” rating. As per Friday, March 11, the company rating was maintained by Brean Capital. Canaccord Genuity maintained Cardiome Pharma Corp. (NASDAQ:CRME) rating on Wednesday, November 15. Canaccord Genuity has “Buy” rating and $5 target. Mackie maintained the stock with “Buy” rating in Wednesday, March 14 report.

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. The company has market cap of $75.65 million. It offers BRINAVESS ) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It currently has negative earnings. The firm also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension.

The stock decreased 1.06% or $0.19 during the last trading session, reaching $17.8. About 39,843 shares traded or 135.67% up from the average. Morgan Stanley Asia-Pacific Fun (APF) has risen 18.37% since April 23, 2017 and is uptrending. It has outperformed by 6.82% the S&P500.

City Of London Investment Management Co Ltd holds 3.59% of its portfolio in Morgan Stanley Asia-Pacific Fun for 2.82 million shares. 1607 Capital Partners Llc owns 1.20 million shares or 1.23% of their US portfolio. Moreover, Bulldog Investors Llc has 1.21% invested in the company for 452,116 shares. The Alabama-based Cornerstone Advisors Inc has invested 0.3% in the stock. Gramercy Funds Management Llc, a Connecticut-based fund reported 32,540 shares.

Cardiome Pharma Corp. (NASDAQ:CRME) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: